{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:54:06Z","timestamp":1790970846494,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the S&T Program of Chengde","award":["202406A026"],"award-info":[{"award-number":["202406A026"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,2]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Gadoteridol, a gadolinium-based contrast agent used for magnetic resonance imaging, has been used in clinical settings since its approval in the United Kingdom in 1992. Although its efficacy in enhancing imaging results is well established, investigating its associated adverse reactions remains critically important. This study aimed to comprehensively assess the safety profile of gadoteridol-related adverse drug events (ADEs), as reported in the FDA Adverse Event Reporting System (FAERS) database. Adverse event reports on gadoteridol spanning from the first quarter of 2004 to the fourth quarter of 2024 were extracted from the FAERS database. The analysis employed 4 complementary signal-detection methods, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayes geometric mean (EBGM), and Bayesian confidence propagation neural network (BCPNN), to identify and evaluate adverse drug event signals. The data were processed and analyzed using R software. During the entire study period, a total of 1158 reports of ADEs related to gadoteridol were identified, with the highest number reported in 2021, accounting for 11.61% of the total reports. Most reports were from patients aged\u2005&gt;\u200560 years, representing 32.36% of the total. Regarding sex distribution, a greater number of reports were filed for female patients (58.17%) than for male patients (37.31%). Geographically, the United States contributed 45.63% of all reports. Notably, adverse reaction outcomes indicated that \u201cother serious\u201d reactions were predominant, accounting for 50.91% of all cases. Signal analysis revealed that, among 19 system organ classes examined, neurological diseases were the most frequently reported (501 cases), followed by systemic diseases (411 cases) and respiratory diseases (376 cases). Specific analyses of adverse reaction signals demonstrated the strongest associations with respiratory illnesses, immune system disorders, and skin-related conditions. This study offers a systematic examination of adverse event signals associated with gadoteridol using data from the FAERS database. These findings highlight notable reporting signals involving neurological, systemic, and immune-related conditions. This information is crucial for clinical practitioners prescribing gadoteridol and may contribute to enhancing patient safety and informing future regulatory actions concerning contrast agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050894","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:01:34Z","timestamp":1790967694000},"page":"e50894","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Real-world evidence on gadoteridol safety"],"prefix":"10.1097","volume":"105","author":[{"given":"Yingwei","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Radiology, The Affiliated Hospital of Chengde Medical University, Chengde, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics of severe trauma, The Affiliated Hospital of Chengde Medical University, Chengde, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Affiliated Hospital of Chengde Medical University, Chengde, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Affiliated Hospital of Chengde Medical University, Chengde, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiquan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Affiliated Hospital of Chengde Medical University, Chengde, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2593-6731","authenticated-orcid":false,"given":"Mingyang","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Hand and Foot Surgery, The Affiliated Hospital of Chengde Medical University, Chengde, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20261002","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00002142-199500730-00004","article-title":"The use of MR contrast in nonneoplastic disease of the brain.","volume":"7","author":"Runge","year":"1995","journal-title":"Top Magn Reson Imaging"},{"key":"R3-20261002","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/jmri.26957","article-title":"Clinical safety of gadoteridol, representative of the macrocyclic class of gadolinium-based contrast agents.","volume":"51","author":"Runge","year":"2020","journal-title":"J Magn Reson Imaging"},{"key":"R4-20261002","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/jmri.24787","article-title":"Basic MR relaxation mechanisms and contrast agent design.","volume":"42","author":"De Le\u00f3n-Rodr\u00edguez","year":"2015","journal-title":"J Magn Reson Imaging"},{"key":"R5-20261002","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1021\/acs.molpharmaceut.9b00908","article-title":"Design of gadoteridol-loaded cationic liposomal adjuvant CAF01 for MRI of lung deposition of intrapulmonary administered particles.","volume":"16","author":"Thakur","year":"2019","journal-title":"Mol Pharm"},{"key":"R6-20261002","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2214\/AJR.10.5992","article-title":"Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.","volume":"197","author":"Hamilton","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"R7-20261002","doi-asserted-by":"crossref","first-page":"rbad035","DOI":"10.1093\/rb\/rbad035","article-title":"Quantitatively relating magnetic resonance T(1) and T(2) to glycosaminoglycan and collagen concentrations mediated by penetrated contrast agents and biomacromolecule-bound water.","volume":"10","author":"Gao","year":"2023","journal-title":"Regen Biomater"},{"key":"R8-20261002","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.acra.2020.01.007","article-title":"Prospective imaging trial assessing gadoteridol retention in the deep brain nuclei of women undergoing breast MRI.","volume":"27","author":"Neal","year":"2020","journal-title":"Acad Radiol"},{"key":"R9-20261002","doi-asserted-by":"crossref","first-page":"e230984","DOI":"10.1148\/radiol.230984","article-title":"Gadolinium-based contrast agent biodistribution and speciation in rats.","volume":"309","author":"Le Fur","year":"2023","journal-title":"Radiology"},{"key":"R10-20261002","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-Associated reports in the FDA Adverse Event Reporting System (FAERS).","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R11-20261002","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA).","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"R12-20261002","doi-asserted-by":"crossref","first-page":"16202","DOI":"10.1038\/s41598-024-67209-0","article-title":"Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database.","volume":"14","author":"Yang","year":"2024","journal-title":"Sci Rep"},{"key":"R13-20261002","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio.","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R14-20261002","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system.","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"R15-20261002","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2147\/TCRM.S321789","article-title":"Adverse events related to off-label drugs using spontaneous adverse event reporting systems.","volume":"17","author":"Han","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"R16-20261002","doi-asserted-by":"crossref","first-page":"119010","DOI":"10.1016\/j.jep.2024.119010","article-title":"Ginkgo biloba extract safety: insights from a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.","volume":"337","author":"Yao","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"R17-20261002","doi-asserted-by":"crossref","first-page":"12828","DOI":"10.1038\/s41598-023-38942-9","article-title":"Modified generalized Weibull distribution: theory and applications.","volume":"13","author":"Shama","year":"2023","journal-title":"Sci Rep"},{"key":"R18-20261002","doi-asserted-by":"crossref","first-page":"484","DOI":"10.21037\/atm.2016.08.45","article-title":"Parametric regression model for survival data: Weibull regression model as an example.","volume":"4","author":"Zhang","year":"2016","journal-title":"Ann Transl Med"},{"key":"R19-20261002","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/RLI.0000000000001180","article-title":"Recent developments and future perspectives in magnetic resonance imaging and computed tomography contrast media.","volume":"61","author":"Frenzel","year":"2026","journal-title":"Invest Radiol"},{"key":"R20-20261002","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neurad.2020.05.008","article-title":"Consensus Guidelines of the French Society of Neuroradiology (SFNR) on the use of Gadolinium-Based Contrast agents (GBCAs) and related MRI protocols in Neuroradiology.","volume":"47","author":"Lersy","year":"2020","journal-title":"J Neuroradiol"},{"key":"R21-20261002","doi-asserted-by":"crossref","first-page":"e026923","DOI":"10.1161\/JAHA.122.026923","article-title":"Contrast-enhanced cardiac magnetic resonance imaging with a manganese-based alternative to gadolinium for tissue characterization of acute myocardial infarction.","volume":"12","author":"Bonner","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R22-20261002","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/RLI.0000000000001072","article-title":"Clinical safety of gadobutrol: review of over 25 years of use exceeding 100 million administrations.","volume":"59","author":"Endrikat","year":"2024","journal-title":"Invest Radiol"},{"key":"R23-20261002","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00415-025-13172-3","article-title":"Safety concerns of maternal antiseizure medications exposure on perinatal and offspring outcomes: a disproportionality analysis based on FDA adverse event reporting system.","volume":"272","author":"Zeng","year":"2025","journal-title":"J Neurol"},{"key":"R24-20261002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12916-024-03537-2","article-title":"Differences in hypersensitivity reactions and gadolinium deposition disease\/symptoms associated with gadolinium exposure to gadolinium-based contrast agents: new insights based on global databases VigiBase, FAERS, and IQVIA-MIDAS.","volume":"22","author":"Qu","year":"2024","journal-title":"BMC Med"},{"key":"R25-20261002","first-page":"1113","article-title":"The reporting frequency of skin lesions in contrast media-induced chemical hypersensitivity.","volume":"17","author":"Iordache","year":"2019","journal-title":"Exp Ther Med"},{"key":"R26-20261002","doi-asserted-by":"crossref","first-page":"111504","DOI":"10.1016\/j.ejrad.2024.111504","article-title":"Assessment of first-time and repeated acute adverse reactions to gadolinium-based contrast agents in MRI: a retrospective study.","volume":"176","author":"Fukushima","year":"2024","journal-title":"Eur J Radiol"},{"key":"R27-20261002","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/jmri.28951","article-title":"Relationship between patient-friendly audiovisual systems and MRI contrast agent to adverse reactions.","volume":"59","author":"Nitta","year":"2024","journal-title":"J Magn Reson Imaging"},{"key":"R29-20261002","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamainternmed.2019.5284","article-title":"Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis.","volume":"180","author":"Woolen","year":"2020","journal-title":"JAMA Intern Med"},{"key":"R30-20261002","doi-asserted-by":"crossref","first-page":"105800","DOI":"10.1016\/j.intimp.2019.105800","article-title":"A mast-cell-specific receptor mediates Iopamidol induced immediate IgE-independent anaphylactoid reactions.","volume":"75","author":"Jiang","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"R31-20261002","doi-asserted-by":"crossref","first-page":"111323","DOI":"10.1016\/j.biopha.2021.111323","article-title":"MRGPRX2 mediates immediate-type pseudo-allergic reactions induced by iodine-containing iohexol.","volume":"137","author":"Yuan","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"R32-20261002","doi-asserted-by":"crossref","first-page":"110874","DOI":"10.1016\/j.intimp.2023.110874","article-title":"Inhibitory effect of daphnetin on the C48\/80-induced pseudo-allergic reaction.","volume":"124","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"R33-20261002","first-page":"741018","article-title":"Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention.","volume":"2014","author":"Andreucci","year":"2014","journal-title":"Biomed Res Int"},{"key":"R34-20261002","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12016-021-08919-5","article-title":"Road less traveled: drug hypersensitivity to fluoroquinolones, vancomycin, tetracyclines, and macrolides.","volume":"62","author":"Zhu","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"R35-20261002","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.imlet.2018.04.004","article-title":"Anti-pseudo-allergy effect of isoliquiritigenin is MRGPRX2-dependent.","volume":"198","author":"Hou","year":"2018","journal-title":"Immunol Lett"},{"key":"R36-20261002","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.neurom.2023.01.007","article-title":"Auricular vagal nerve stimulation inhibited central nerve growth factor\/tropomyosin receptor kinase A\/Phospholipase C-Gamma signaling pathway in functional dyspepsia model rats with gastric hypersensitivity.","volume":"27","author":"Zhou","year":"2024","journal-title":"Neuromodulation"},{"key":"R37-20261002","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1177\/02841851211034038","article-title":"Gadoteridol-enhanced MRI of the breast: can contrast agent injection rate impact background parenchymal enhancement?","volume":"63","author":"Marzocca","year":"2022","journal-title":"Acta Radiol"},{"key":"R39-20261002","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4329\/wjr.v16.i6.168","article-title":"Navigating nephrotoxic waters: a comprehensive overview of contrast-induced acute kidney injury prevention.","volume":"16","author":"Theofilis","year":"2024","journal-title":"World J Radiol"},{"key":"R40-20261002","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/RMR.0000000000000106","article-title":"Preventing allergic reactions to gadolinium-based contrast agents.","volume":"25","author":"Heshmatzadeh Behzadi","year":"2016","journal-title":"Top Magn Reson Imaging"},{"key":"R41-20261002","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2174\/1389200220666191021094906","article-title":"Sexual dimorphism in drug metabolism and pharmacokinetics.","volume":"20","author":"Valodara","year":"2019","journal-title":"Curr Drug Metab"},{"key":"R42-20261002","doi-asserted-by":"crossref","first-page":"102595","DOI":"10.1016\/j.coi.2025.102595","article-title":"Sex hormones and epigenetic dysregulation in autoimmune disease.","volume":"95","author":"Dai","year":"2025","journal-title":"Curr Opin Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:01:39Z","timestamp":1790967699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050894"}},"subtitle":["A 20-year FAERS database study revealing critical adverse reaction patterns"],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":39,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050894","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"2025-03-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}